Intralesional meglumine antimoniate for cutaneous leishmaniasis: Evidence from a prospective real-world study in the Brazilian Amazon

IL-MA demonstrated favorable safety and moderate-to-high effectiveness, supporting its use as a pragmatic therapeutic option for CL in the Amazon region. The integration of mHealth tools proved valuable for remote monitoring and minimizing loss to follow-up, offering a promising approach for patient management and the generation of real-world evidence in endemic settings.